dc.contributor.author | Arce Vargas, F | |
dc.contributor.author | Furness, AJS | |
dc.contributor.author | Solomon, I | |
dc.contributor.author | Joshi, K | |
dc.contributor.author | Mekkaoui, L | |
dc.contributor.author | Lesko, MH | |
dc.contributor.author | Miranda Rota, E | |
dc.contributor.author | Dahan, R | |
dc.contributor.author | Georgiou, A | |
dc.contributor.author | Sledzinska, A | |
dc.contributor.author | Ben Aissa, A | |
dc.contributor.author | Franz, D | |
dc.contributor.author | Werner Sunderland, M | |
dc.contributor.author | Wong, YNS | |
dc.contributor.author | Henry, JY | |
dc.contributor.author | O'Brien, T | |
dc.contributor.author | Nicol, D | |
dc.contributor.author | Challacombe, B | |
dc.contributor.author | Beers, SA | |
dc.contributor.author | Melanoma TRACERx Consortium, | |
dc.contributor.author | Renal TRACERx Consortium, | |
dc.contributor.author | Lung TRACERx Consortium, | |
dc.contributor.author | Turajlic, S | |
dc.contributor.author | Gore, M | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Chester, KA | |
dc.contributor.author | Pule, M | |
dc.contributor.author | Ravetch, JV | |
dc.contributor.author | Marafioti, T | |
dc.contributor.author | Peggs, KS | |
dc.contributor.author | Quezada, SA | |
dc.date.accessioned | 2017-05-08T09:27:08Z | |
dc.date.issued | 2017-04-18 | |
dc.identifier.citation | Immunity, 2017, 46 (4), pp. 577 - 586 | |
dc.identifier.issn | 1074-7613 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/635 | |
dc.identifier.eissn | 1097-4180 | |
dc.identifier.doi | 10.1016/j.immuni.2017.03.013 | |
dc.description.abstract | CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology. | |
dc.format | Print-Electronic | |
dc.format.extent | 577 - 586 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CELL PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Melanoma TRACERx Consortium | |
dc.subject | Renal TRACERx Consortium | |
dc.subject | Lung TRACERx Consortium | |
dc.subject | Cell Line, Tumor | |
dc.subject | K562 Cells | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Neoplasms | |
dc.subject | Receptors, IgG | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Immunotherapy | |
dc.subject | Lymphocyte Depletion | |
dc.subject | Flow Cytometry | |
dc.subject | Protein Binding | |
dc.subject | Immunoglobulin Fc Fragments | |
dc.subject | T-Lymphocytes, Regulatory | |
dc.subject | Interleukin-2 Receptor alpha Subunit | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Programmed Cell Death 1 Receptor | |
dc.title | Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-02-09 | |
rioxxterms.versionofrecord | 10.1016/j.immuni.2017.03.013 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2017-04-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Immunity | |
pubs.issue | 4 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 46 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Melanoma and Kidney Cancer | |
dc.contributor.icrauthor | Furness, Andrew | |